Swiss anti-infectives specialist Basilea Pharmaceutica has entered a research collaboration with U.S.-based Prokaryotics to develop a novel broad-spectrum antifungal aimed at treating severe invasive fungal infections, the companies announced on January 7th 2026.
The new year at Cologne-based Disco Pharma has begun much as the old one ended: with a headline-grabbing announcement. Just weeks after closing a sizeable financing round, the company has now unveiled an equally notable collaboration with US biotech pioneer Amgen, a partnership with a potential value of up to US$618 million.
Novo Nordisk is putting down up to US$362m to tap into Ascendis’ TransCon technology for treatments in metabolic and cardiovascular diseases. The pharma powerhouse has its sights set on developing a once-monthly GLP-1 receptor agonist.
Italian obesity gene therapy developer Resalis Therapeutics srl has gained an equity investment from French pharma major Sanofi SA sufficient to finance its miRNA-22 antisense blocker RES-010 through Phase II proof-of-concept.
Viennese biotech QUANTRO Therapeutics identifies small molecule targeting an onkogenic transcription factor in Boehringer Ingelheim collab.
ALS specialist NeuroSense Therapeutics Ltd announces it will be collaborating with Swiss Lonza AG to identify exosome-based biomarkers to advance theranostics in neurodegeneration.
Boehringer Intelheim is expanding its antfibrotics pipeline licencing a first-in-class treatment for fibro-inflammatory diseases from Kyowa Kirin Co. Ltd.
Following its announcement from Oktober 2023 to take over the filgotinib business from Galapagos NV, Bologna-based Alfasigma SpA has signed the €170m deal.
Swiss LimmaTech Biologics and AbVacc Inc have agreed to co-develop AbVacc’s preclinical Staphylococcus aureus vaccine LBT-SA7 (formerly IBT-V02) in case of Phase I success.
Due to the global niche character of pharmaceutical biotechnology, research collaborations and market entries on an international level are essential. Agility and market knowledge are required to maintain an overview in a rapidly evolving environment and to initiate a sustainable internationalisation process.
Genentech Corp. / Roche
Novo Nordisk
Resalis/Vimeo